Shionogi Inc. (U.S.)

BREAKING NEWS: SCORPIO-PEP, a global Phase 3 post-exposure prophylaxis study of our investigational oral antiviral, met its primary endpoint. This is the first and only Phase 3 trial of an oral antiviral to show reduction in the proportion of participants who test positive for SARS-CoV2 and develop COVID-19 symptoms after exposure to household contacts when compared to placebo. Read the release here: https://lnkd.in/e4APcNwU

Carbapenem resistance continues to emerge among high priority pathogens, which may further limit treatment options. Ongoing evaluations of antibiotic activity against problematic pathogens are critical to inform appropriate use.   This year at #IDWeek2024, Boudewijn de Jonge, PhD, Director, Microbiology at Shionogi Inc., will present new data on the activity of our antibiotic against certain Gram-negative bacterial infections. https://bit.ly/3BW5RC0

Today at IDWeek, we debuted the new #AMRWarrior, an evolution in our efforts to raise awareness of the global threat of antimicrobial resistance.   Don’t miss this #AI experience and the chance to see yourself fiercely standing up to AMR.   Check out some of our favorites and get your #AMRWarrior tomorrow at Booth 332.

Antibiotic-resistant infections are becoming more prevalent around the world, making them difficult-to-treat.   At #IDWeek2024, we’re sharing real world and preclinical data on our antibiotic in adults with certain Gram-negative bacterial infections. Learn more: https://bit.ly/3BW5RC0

The #AMRWarrior is back. Join us in the fight against Antimicrobial Resistance (#AMR), one of the top global public health threats. Starting tomorrow at IDWeek, discover your warrior at Booth 322. #InfectiousDisease

Real-world evidence can enhance our understanding of how treatments may perform in clinical settings. At #IDWeek2024, we are presenting data from PROVE, the largest global real-world study on our antibiotic in adults with certain Gram-negative bacterial infections. Learn more: https://bit.ly/3BW5RC0

We have entered into an agreement with Next Gen Diagnostics to develop sequence-based models to predict bacterial susceptibility to our antibiotic for the treatment of certain Gram-negative bacterial infections. This agreement is part of our efforts to ensure clinicians have novel testing options to support appropriate use of our antibiotic. Learn more: https://lnkd.in/gH2a3Av5

Happening alongside #IDWeek2024, Michael Dudley, PharmD, President and CEO of Qpex Biopharma, a Shionogi Group Company, will deliver the keynote address at the Society of Infectious Diseases Pharmacists (SIDP) Annual Meeting on October 15th. As a Co-founder of SIDP, Dr. Dudley will offer insights into his journey from academic research and teaching to a career in R&D. His work has led to the discovery, development and regulatory approval of four antibiotics, providing a roadmap for a strong and sustainable global antimicrobial pipeline. #SIDP2024 #InfectiousDiseases #Pharmacists

Infections caused by superbugs are increasing, and there are not enough drugs in development to address the continuing threat of resistance. We need to incentivize the development of critically needed antibiotics and antifungals through the passage of the PASTEUR Act.    Infectious Diseases Society of America is making it easy for you to contact your state's government representative to ask them to #PassPASTEUR. Help advance this important policy by making your opinion count with the help of the IDSA tool: https://lnkd.in/gAHTC73P 

We recently attended the National Fragile X Foundation Conference and had the privilege to meet with many members of the Fragile X community, including people with Fragile X, caregivers, researchers and professionals. We learned about their challenges and hopes for the future, including the need for additional treatment options. We look forward to partnering with the Fragile X community on research and advocacy efforts in the years ahead. Learn more about our Fragile X clinical research program. https://lnkd.in/eX5RDFYV